NanoString Technologies, Inc. provides life science tools for translational research and molecular diagnostic products worldwide. The company offers nCounter Analysis System, an automated, multi-application, digital detection, and counting system. It provides nCounter MAX and FLEX systems that include Prep Station, an automated liquid handling component that processes and prepares samples for data collection; and nCounter Digital Analyzer, which collects data from samples by taking images of the immobilized fluorescent reporters in the sample cartridge and processing the data into output files. The company also offers nCounter SPRINT Profiler, an instrument that provides liquid handling steps and the digital analysis through use of a microfluidic cartridge; and nSolver Analysis Software, a data analysis program that enables researchers to check, normalize, and analyze their data. In addition, it provides custom CodeSets; and Pan Cancer and 360 gene expression, protein immune profiling, neuropathology and neuro-inflammation gene expression, autoimmune disease gene expression, nCounter Vantage 3D, miRNA expression, cancer copy number variation, and other gene expression panels. Further, the company offers nCounter-based reagents that allow users to design customized assays; Master Kits, such as ancillary reagents and plasticware to setup and process samples in the nCounter Prep Station and nCounter Digital Analyzer; and nCounter Dx Analysis System and Prosigna molecular diagnostic test kits. It has collaboration with Celgene Corporation; Merck & Co., Inc.; Medivation, Inc.; and Astellas Pharma, Inc., as well as the Cancer Therapy Evaluation Program of the National Cancer Institute. The company was founded in 2003 and is headquartered in Seattle, Washington.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Phone206-378-6266
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$106.73 million
Profitability
Miscellaneous
Employees476
Next Earnings Date5/14/2019 (Estimated)
OptionableOptionable
NanoString Technologies (NASDAQ:NSTG) Frequently Asked Questions
What is NanoString Technologies' stock symbol?
NanoString Technologies trades on the NASDAQ under the ticker symbol "NSTG."
How were NanoString Technologies' earnings last quarter?
NanoString Technologies Inc (NASDAQ:NSTG) announced its earnings results on Thursday, March, 7th. The biotechnology company reported ($0.68) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.50) by $0.18. The biotechnology company earned $30.03 million during the quarter. NanoString Technologies had a negative net margin of 72.52% and a negative return on equity of 252.59%. View NanoString Technologies' Earnings History.
When is NanoString Technologies' next earnings date?
What guidance has NanoString Technologies issued on next quarter's earnings?
NanoString Technologies updated its FY 2019 earnings guidance on Thursday, March, 7th. The company provided earnings per share (EPS) guidance of $-2.45--2.3 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $-2.02. The company issued revenue guidance of $118-123 million, compared to the consensus revenue estimate of $122.74 million.
What price target have analysts set for NSTG?
4 brokerages have issued 1 year price targets for NanoString Technologies' stock. Their predictions range from $18.00 to $35.00. On average, they expect NanoString Technologies' share price to reach $23.50 in the next year. This suggests a possible upside of 0.3% from the stock's current price. View Analyst Price Targets for NanoString Technologies.
What is the consensus analysts' recommendation for NanoString Technologies?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NanoString Technologies in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for NanoString Technologies.
Has NanoString Technologies been receiving favorable news coverage?
Media coverage about NSTG stock has trended neutral recently, according to InfoTrie Sentiment. The research group rates the sentiment of news coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. NanoString Technologies earned a media sentiment score of 0.2 on InfoTrie's scale. They also gave news stories about the biotechnology company a news buzz of 3.0 out of 10, indicating that recent news coverage is unlikely to have an impact on the company's share price in the near term.
Who are some of NanoString Technologies' key competitors?
Some companies that are related to NanoString Technologies include Repligen (RGEN), Acceleron Pharma (XLRN), Halozyme Therapeutics (HALO), Aerie Pharmaceuticals (AERI), Regenxbio (RGNX), Crispr Therapeutics (CRSP), Denali Therapeutics (DNLI), Atara Biotherapeutics (ATRA), Audentes Therapeutics (BOLD), Orchard Therapeutics (ORTX), Rubius Therapeutics (RUBY), Momenta Pharmaceuticals (MNTA), Alector (ALEC), Iovance Biotherapeutics (IOVA) and Editas Medicine (EDIT).
What other stocks do shareholders of NanoString Technologies own?
Who are NanoString Technologies' key executives?
NanoString Technologies' management team includes the folowing people:
- Mr. R. Bradley Gray, CEO, Pres & Director (Age 42)
- Mr. J. Chad Brown, Sr. VP of Sales & Marketing (Age 61)
- Dr. Joseph M. Beechem, Sr. VP of R&D (Age 61)
- Mr. K. Thomas Bailey M.B.A., CFO & Treasurer (Age 50)
- Dr. Mary Tedd Allen, Sr. VP of Operations (Age 56)
Who are NanoString Technologies' major shareholders?
NanoString Technologies' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (7.17%), Broadfin Capital LLC (2.34%), Polar Capital LLP (1.95%), Millennium Management LLC (1.15%), Geode Capital Management LLC (1.09%) and Geode Capital Management LLC (1.09%). Company insiders that own NanoString Technologies stock include David W Ghesquiere, Lifesciences Ii LP Clarus, Mary Tedd Allen, Nicholas Galakatos, R Bradley Gray and William Young. View Institutional Ownership Trends for NanoString Technologies.
Which institutional investors are selling NanoString Technologies stock?
NSTG stock was sold by a variety of institutional investors in the last quarter, including Broadfin Capital LLC, D. E. Shaw & Co. Inc., Algert Global LLC, Two Sigma Investments LP, Weiss Multi Strategy Advisers LLC, Bank of America Corp DE, Northern Trust Corp and MetLife Investment Advisors LLC. Company insiders that have sold NanoString Technologies company stock in the last year include Lifesciences Ii LP Clarus, Mary Tedd Allen, Nicholas Galakatos and R Bradley Gray. View Insider Buying and Selling for NanoString Technologies.
Which institutional investors are buying NanoString Technologies stock?
NSTG stock was purchased by a variety of institutional investors in the last quarter, including Millennium Management LLC, Polar Capital LLP, Mackay Shields LLC, Geode Capital Management LLC, Geode Capital Management LLC, Squarepoint Ops LLC, Acadian Asset Management LLC and California Public Employees Retirement System. View Insider Buying and Selling for NanoString Technologies.
How do I buy shares of NanoString Technologies?
Shares of NSTG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is NanoString Technologies' stock price today?
One share of NSTG stock can currently be purchased for approximately $23.44.
How big of a company is NanoString Technologies?
NanoString Technologies has a market capitalization of $728.52 million and generates $106.73 million in revenue each year. The biotechnology company earns $-77,400,000.00 in net income (profit) each year or ($2.78) on an earnings per share basis. NanoString Technologies employs 476 workers across the globe.
What is NanoString Technologies' official website?
How can I contact NanoString Technologies?
NanoString Technologies' mailing address is 530 FAIRVIEW AVENUE NORTH SUITE 2000, SEATTLE WA, 98109. The biotechnology company can be reached via phone at 206-378-6266 or via email at [email protected]
MarketBeat Community Rating for NanoString Technologies (NASDAQ NSTG)
MarketBeat's community ratings are surveys of what our community members think about NanoString Technologies and other stocks. Vote "Outperform" if you believe NSTG will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NSTG will underperform the S&P 500 over the long term. You may vote once every thirty days.
